MRC Technology, an independent life science medical research charity, has appointed Andrew Mercieca as its Finance Director from 1 April 2015. Andrew joined the company as Interim Finance Director in August 2014. He brings a wealth of senior international finance experience from previous roles at leading technology and pharmaceutical companies, including Syniverse Technologies, Astellas Pharma and Merck Serono.
Dave Tapolczay, Chief Executive Officer, MRC Technology said: “Andrew has been a great asset to the Executive Team and the business since he joined last summer. MRC Technology is increasing its global partnerships, and Andrew’s EMEA, Asia and USA experience is a valued contribution to our drive to improve health through science across the world.”
Andrew Mercieca responded, saying: “MRC Technology has an impressive track record of connecting promising research with industry to ensure it fulfils its potential and making treatments available to patients, and I am very pleased to be supporting these efforts.”